Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:24 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Vitrolife - Update ahead of 2023

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Vitrolife - Update ahead of 2023

2023-02-16 08:25:00

Vitrolife is in good health and the company ended 2022 on a strong finish and a positive outlook ahead for the rest of 2023. We point to both improved margins and improved organic growth. Vitrolife is in a good position to benefit from operational leverage and complementary acquisitions. Our updated view is a base case valuation of SEK 285 (230) and a Bull Case of SEK 400 (350), and a Bear Case of SEK 140 (140).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/